IP Library Granted Patent US 9,132,092
Granted Patent B1
US 9,132,092 · App. 14/326,949 · Granted Sep 15, 2015

Pharmaceutical composition of doxycycline

Inventors: Ravish Kumar Sharma (Khargone, IN); Pulak Kumar Metia (Howrah, IN); Ravinder Singh (Gurgaon, IN); Rajesh Srikrishan Shear (Gurgaon, IN); Anuj Kumar Fanda (Ghaziabad, IN); Satish Kumar Jain (Bilaspur, IN); Romi Barat Singh (Varanasi, IN); Swarna Pappu (Monroe, NJ); Prabhakar Konatham (Monmouth Junction, NJ); Pruthvipathy Katikaneni (Parsippany, NJ)
Assignee: RANBAXY LABORATORIES LIMITED
A61K9/2054A61K9/2009A61K9/209A61K9/2013A61K9/2027A61K31/65
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,132,092
App. No.
14/326,949
Granted
Sep 15, 2015
Kind
B1
Abstract

The present invention relates to a pharmaceutical composition comprising (i) 50% to 99% of doxycycline as an immediate-release portion; (ii) 1% to 50% of doxycycline as a controlled-release portion; and (iii) one or more pharmaceutically acceptable excipients; wherein the pharmaceutical composition provides a total daily dosage of 40 mg when administered once daily. It also relates to process for preparation of the pharmaceutical composition and its use for treating rosacea.

Claims (15)

1. A pharmaceutical composition comprising (i) 50-99% of doxycycline and one or more pharmaceutically acceptable excipients as an immediate-release portion; and (ii) 1-50% of doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients as a controlled-release portion, wherein the pharmaceutical composition provides a total daily dosage of 40 mg when administered once daily.

2. The pharmaceutical composition according to claim 1 , wherein the immediate-release portion contains 75% of doxycycline and the controlled-release portion contains 25% of doxycycline.

3. The pharmaceutical composition according to claim 1 , wherein the immediate-release portion contains 30 mg of doxycycline and the controlled-release portion contains 10 mg of doxycycline.

4. The pharmaceutical composition according to claim 1 , wherein the immediate-release portion contains 65% of doxycycline and the controlled-release portion contains 35% of doxycycline.

5. The pharmaceutical composition according to claim 1 , wherein the immediate-release portion contains 26 mg of doxycycline and the controlled-release portion contains 14 mg of doxycycline.

6. The pharmaceutical composition according to claim 1 , wherein the immediate-release portion contains 60% of doxycycline and the controlled-release portion contains 40% of doxycycline.

7. The pharmaceutical composition according to claim 1 , wherein the immediate-release portion contains 24 mg of doxycycline and the controlled-release portion contains 16 mg of doxycycline.

8. The pharmaceutical composition according to claim 1 , wherein the controlled-release polymer is a cellulose polymer.

9. The pharmaceutical composition according to claim 1 , wherein the one or more pharmaceutically acceptable excipients are selected from the group comprising binders, diluents, disintegrants, lubricants/glidants/antiadherants, plasticizers, or mixtures thereof.

10. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is in the form of tablet.

11. A process for the preparation of a pharmaceutical composition comprising (i) 50% to 99% of doxycycline and one or more pharmaceutically acceptable excipients as an immediate-release portion; and (ii) 1% to 50% of doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients as a controlled-release portion, wherein the pharmaceutical composition provides a total daily dosage of 40 mg when administered once daily, and wherein the process comprises:

a) preparing the immediate-release portion comprising doxycycline and one or more pharmaceutically acceptable excipients;

b) preparing the controlled-release portion comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients; and

c) processing the immediate-release portion and the controlled-release portion to form the pharmaceutical composition.

12. A method of treating rosacea by administering to a patient in need thereof a pharmaceutical composition comprising (i) 50% to 99% of doxycycline and one or more pharmaceutically acceptable excipients as an immediate-release portion; and (ii) 1% to 50% of doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients as a controlled-release portion, wherein the pharmaceutical composition provides a total daily dosage of 40 mg when administered once daily.

Assignments (2)
MERGER Recorded Jan 13, 2016
From: RANBAXY LABORATORIES LIMTED
To: SUN PHARMACEUTICAL INDUSTRIES LIMITED
Reel/Frame 037513/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2014
From: SHARMA, RAVISH KUMAR; METIA, PULAK KUMAR; SINGH, RAVINDER; SHEAR, RAJESH SRIKRISHAN; FANDA, ANUJ KUMAR; JAIN, SATISH KUMAR; SINGH, ROMI BARAT; PAPPU, SWARNA; KONATHAM, PRABHAKAR; KATIKANENI, PRUTHVIPATHY
To: RANBAXY LABORATORIES LIMITED
Reel/Frame 033873/0728 →